

Balaxi Pharmaceuticals Limited

Date: 31st August, 2026

To,
Listing Department,
National Stock Exchange of India Limited
Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

NSE Symbol: BALAXI

Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Receipt of WHO-GMP Certification for Company's Pharmaceutical Formulation Manufacturing Facility

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform you that **Balaxi Pharmaceuticals Limited ("Company")** has received the **WHO-GMP (Good Manufacturing Practices) Certification** for its first pharmaceutical formulation manufacturing facility located at **Jadcherla, Hyderabad, Telangana**.

The WHO-GMP Certification has been issued by the **Licensing Authority, Government of Telangana**, following the inspection of the Company's manufacturing facility conducted on **14th July, 2026**. The certificate is dated **27th August, 2026** and is valid up to **26th August, 2029**.

The receipt of the WHO-GMP Certification marks a **significant milestone in the Company's journey towards establishing its own manufacturing capabilities** and further strengthens its quality and manufacturing credentials.

The Company has commenced manufacturing of its **initially approved products** at the facility as it awaits approval for some additional products and, going forward, will **progressively add more products to strengthen and expand its product portfolio for its target international markets**, subject to applicable regulatory requirements and approvals.

The requisite details as prescribed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, are enclosed herewith as **Annexure A**.

We request you to kindly take the above information on record.

The same will also be available on the Company's website at www.balaxipharma.in

Thanking You.

Yours faithfully,
For Balaxi Pharmaceuticals Limited

Aman Purohit
(Company Secretary & Compliance Officer)
ICSI Membership No.: A59345

(Encl: As above)

Registered Office:

Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase III, Road No. 81, Jubilee Hills, Hyderabad (T.G.) - 500 096

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in

Annexure A

Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sr. No.	Particulars	Brief Details
1.	Name of the authority	Licensing Authority, Government of Telangana
2.	Nature and details of the action(s) taken, initiated or order(s) passed	The Company has received WHO-GMP Certification for its first pharmaceutical formulation manufacturing facility located at Jadcherla, Hyderabad, Telangana, following the inspection conducted by the Licensing Authority, Government of Telangana. The certification confirms compliance of the site with Good Manufacturing Practices for the certified dosage form, categories and activities.
3.	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	27 th August, 2026
4.	Details of the violation(s) / contravention(s) committed or alleged to be committed	Not Applicable
5.	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	The receipt of WHO-GMP Certification is a significant milestone for the Company and strengthens its manufacturing and quality credentials. The Company intends to commence manufacturing of its initial set of products at the facility and progressively add more products to strengthen and expand its product portfolio for its target international markets. The Company does not anticipate any adverse impact on its existing business operations.

Registered Office:

Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase III, Road No. 81, Jubilee Hills, Hyderabad (T.G.) - 500 096

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in